Table 2. Relative hazards of starting DAA from fitting a Cox regression model.
| Relative hazards of starting DAA | ||||
|---|---|---|---|---|
| Unadjusted RH (95% CI) | p-value | Adjusted HR (95% CI) | p-value | |
| Age, years | ||||
| >50 years vs. below | 1.5 (1.3, 1.8) | < .001 | 1.5 (1.2, 1.8) | < .001 |
| Gender | ||||
| Female vs. Male | 1.0 (0.9, 1.2) | 0.8 | 1.1 (0.9, 1.4) | 0.2 |
| Mode of HIV Transmission | ||||
| Heterosexual contacts | 1.0 | 1.0 | ||
| IDU | 1.1 (0.9, 1.4) | 0.5 | 1.0 (0.8, 1.4) | 0.7 |
| Homosexual contacts | 1.2 (0.8, 1.8) | 0.5 | 1.3 (0.8, 2.1) | 0.3 |
| Other/Unknown | 1.1 (0.8, 1.6) | 0.4 | 1.2 (0.8, 1.8) | 0.3 |
| Employment | ||||
| Unemployed | 1.0 | 1.0 | ||
| Employed | 1.2 (1.0, 1.5) | 0.1 | 1.1 (0.9, 1.5) | 0.4 |
| Other/unknown | 1.1 (0.8, 1.5) | 0.6 | 1.1 (0.7, 1.5) | 0.8 |
| CD4 count, cells/mm3 | ||||
| per 100 higher | 1.0 (1.0, 1.0) | 0.5 | 1.0 (0.9, 1.00) | 0.04 |
| HIV-RNA, copies/mL | ||||
| 0–50 vs. >50 | 1.2 (1.0, 1.4) | 0.1 | 1.6 (1.2, 2.1) | < .001 |
| Time from HIV diagnosis, years | ||||
| per 10 longer | 0.9 (0.8, 1.0) | 0.02 | 0.9 (0.8, 1.0) | 0.2 |
| HCV genotype | ||||
| 1a | 1.0 | 1.0 | ||
| 1b | 0.8 (0.6, 1.0) | 0.07 | 0.8 (0.6, 1.1) | 0.1 |
| 2 | 0.7 (0.4, 1.1) | 0.15 | 0.6 (0.3, 1.1) | 0.09 |
| 3 | 0.8 (0.7, 1.0) | 0.04 | 0.7 (0.6, 0.9) | 0.008 |
| 4 | 1.0 (0.8, 1.3) | 0.7 | 1.0 (0.8, 1.3) | 0.7 |
| Other/unknown | 0.6 (0.3, 1.0) | 0.03 | 0.6 (0.3, 1.2) | 0.1 |
| HCV-RNA, log10 IU/L | ||||
| per log higher | 1.0 (0.9, 1.0) | 0.4 | 1.0 (0.9, 1.1) | 0.7 |
| Fib4 | ||||
| 0–1.45 | 1.0 | 1.0 | ||
| 1.46–3.25 | 1.2 (0.9, 1.5) | 0.2 | 1.0 (0.8, 1.4) | 0.9 |
| 3.25+ | 1.0 (0.7, 1.2) | 0.7 | 0.7 (0.5, 1.1) | 0.1 |
| Decompensated cirrhosis | ||||
| Yes vs. No | 1.0 (0.8, 1.2) | 0.9 | 0.9 (0.7, 1.3) | 0.7 |
| Diabetes | ||||
| Yes vs. No | 1.1 (0.9, 1.4) | 0.4 | 1.1 (0.8, 1.5) | 0.4 |
| Platelets, x 109/L | ||||
| >150 vs. below | 0.9 (0.8, 1.1) | 0.4 | 0.9 (0.7, 1.1) | 0.2 |
| ALT, IU/L | ||||
| >2 ULN vs. below | 1.1 (0.9, 1.2) | 0.4 | 1.1 (0.9, 1.4) | 0.2 |
| Bilirubin, IU/L | ||||
| per 10 higher | 1.0 (0.4, 2.1) | 0.9 | 1.0 (0.4, 2.4) | 0.9 |
| eGFR, mL/min/1.73m2 | ||||
| 90+ | 1.0 | 1.0 | ||
| 60–90 | 1.1 (0.9, 1.3) | 0.3 | 0.9 (0.6, 1.3) | 0.6 |
| 0–60 | 0.8 (0.6, 1.2) | 0.3 | 1.1 (0.9, 1.3) | 0.6 |
| Previous failure of HCV treatment | ||||
| Yes vs. No | 1.2 (1.1, 1.4) | 0.004 | 1.2 (1.0, 1.4) | 0.1 |
Adjusted HR: adjusted for all factors examined in table and stratified by cohort.